We are no longer accepting test requisition forms for C3 funded molecular testing through either OncoHelix or UHN.
Please do not submit forms directly to UHN or OncoHelix,
they will not be able to fulfill the test order.
All test requisition forms for C3-funded molecular testing must have been submitted by December 31, 2025. Cases with requisitions submitted by this date will be processed even if the tissue sample arrives after December 31, provided that the patient meets the established eligibility criteria.
​​
If you have any questions please contact us at c3@ohri.ca.
Canada (à l'exception du Québec)
C3 s'est associé à divers fournisseurs de services pour offrir des tests moléculaires dans différentes régions du Canada.
-
Pour l'Ontario, C3 couvrira les tests moléculaires fournis par UHN's Laboratory Medicine Program
-
Pour toutes les autres régions du Canada (à l'exception du Québec*), C3 couvrira les tests moléculaires fournis par OncoHelix
​​
Pour que les tests soient couverts par C3, le patient doit être membre de C3.
Veuillez référer vos patients à "Rejoindre C3" en allant sur www.cholangio.ca/join.
Toute commande de test pour des patients non inscrits entraînera des retards ou, pour les patients de l'Ontario, pourrait aboutir à ne recevoir que les soins standard pour les tests FGFR.
Veuillez cliquer ci-dessous pour des instructions plus détaillées :
Québec
​
Le Québec est à l'avant-garde en matière de financement provincial pour le séquençage génomique large (CGP) NGS et couvre les tests moléculaires via le Centre universitaire de santé McGill (CUSM) - OPTILAB.
Veuillez cliquer ci-dessous pour des instructions détaillées :
Conclusion of the C3 Molecular Testing Program – December 31, 2025
Since our launch in July 2024, the C3 Molecular Testing Program has had a large impact in advancing precision oncology for biliary tract cancer in Canada. In just 18 months, more than 250 patients have undergone molecular testing through this initiative, supported by over 120 clinicians nationwide. We estimate that 40–50%* of completed tests identified a potentially actionable genomic alteration, underscoring the value of molecular testing in expanding clinical options beyond the standard of care.
As we reflect on the impact of the program, we are deeply grateful for the engagement and dedication of clinicians across Canada. Your participation has helped patients gain access to targeted therapies and clinical trials, and has contributed valuable data to the C3 Patient Registry, strengthening the national understanding of biliary tract cancer.
​
Although this program is ending, C3 remains committed to supporting both patients and physicians.
We will continue to provide:​
-
Information on Clinical Trials and how to access Molecular Testing in Canada
-
Data collection for our C3 Patient Registry to generate Real World Evidence
-
Educational resources for physicians and patients
-
Case Presentations through our C3 National BTC Multidisciplinary Rounds
-
Advocacy for molecular testing for biliary tract cancer in Canada
*Final analysis of program impact is still underway and may differ from this early estimate